Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

NCT01596751 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: PLX3397
DRUG: Eribulin

Sponsor

Hope Rugo, MD

Collaborators

[object Object]
[object Object]